<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178268</url>
  </required_header>
  <id_info>
    <org_study_id>10-387</org_study_id>
    <nct_id>NCT01178268</nct_id>
  </id_info>
  <brief_title>XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)</brief_title>
  <official_title>XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, active-controlled, open label, parallel two-arm,
      multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER
      SELECT PLUS Sirolimus-Eluting Coronary Stent System (SECSS) (&quot;CYPHER SELECT PLUS&quot;) during
      commercial use in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

        -  Confirm the safety and effectiveness of the XIENCE V EECSS for the treatment of patients
           in China

        -  Evaluate patient compliance with dual antiplatelet therapy (DAPT)

        -  Evaluate physician-determined XIENCE V EECSS acute performance, deliverability, and
           resource utilization
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent Late Loss (LL)</measure>
    <time_frame>&gt;=13 months</time_frame>
    <description>This is the primary angiographic endpoint.
In-stent LL: The difference between the minimum lumen diameter (MLD) immediately after stent deployment and the MLD at follow-up (within stent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemia-driven Target Vessel Failure (ID-TVF)</measure>
    <time_frame>12 months</time_frame>
    <description>This is the primary efficacy endpoint. Ischemia-driven target vessel failure is defined as the composite of cardiac death, all myocardial infarction (MI) and ischemia-driven target vessel revascularization (ID-TVR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Composite of ST (Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave)</measure>
    <time_frame>12 months</time_frame>
    <description>The primary composite safety endpoint was the incidence of the composite of ST (definite and probable), all death (cardiac, vascular and non-cardiovascular), and all MI (including Q-wave and non-Q-wave).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Vessel Failure (ID-TVF)</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of composite of cardiac death, all MI (including Q-wave and non- Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Vessel Failure (ID-TVF)</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of composite of cardiac death, all MI (including Q-wave and non- Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Vessel Failure (ID-TVF)</measure>
    <time_frame>9 months</time_frame>
    <description>Incidence of composite of cardiac death, all MI (including Q-wave and non- Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Vessel Failure (ID-TVF)</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of composite of cardiac death, all MI (including Q-wave and non- Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave).</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Lesion Revascularization (ID-TLR) (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])</measure>
    <time_frame>12 months</time_frame>
    <description>The is the major Secondary Efficacy Endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Lesion Failure (ID-TLF)</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of composite of cardiac death, MI attributed to the TV and ID-TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Lesion Failure (ID-TLF)</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of composite of cardiac death, MI attributed to the TV and ID-TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Lesion Failure (ID-TLF)</measure>
    <time_frame>9 months</time_frame>
    <description>This is one of the Secondary Composite Endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Lesion Failure (ID-TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>This is one of the Secondary Composite Endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven Target Lesion Failure (ID-TLF)</measure>
    <time_frame>24 months</time_frame>
    <description>This is one of the Secondary Composite Endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</measure>
    <time_frame>30 days</time_frame>
    <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</measure>
    <time_frame>6 months</time_frame>
    <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</measure>
    <time_frame>9 months</time_frame>
    <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</measure>
    <time_frame>12 months</time_frame>
    <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</measure>
    <time_frame>24 months</time_frame>
    <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization (TLR, TVR, and Non-TVR)</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization (TLR, TVR, and Non-TVR)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization (TLR, TVR, and Non-TVR)</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization (TLR, TVR, and Non-TVR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization (TLR, TVR, and Non-TVR)</measure>
    <time_frame>24 months</time_frame>
    <description>One of the Secondary Safety Endpoint was all revascularization rates (target lesion, target vessel, non-target lesion, and non-target vessel) (PCI and CABG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>30 days</time_frame>
    <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>6 months</time_frame>
    <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>9 months</time_frame>
    <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>12 months</time_frame>
    <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>24 months</time_frame>
    <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Protocol MI (Including Q-wave or Non-Q-wave)</measure>
    <time_frame>30 days</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Protocol MI (Including Q-wave or Non-Q-wave)</measure>
    <time_frame>6 months</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Protocol MI (Including Q-wave or Non-Q-wave)</measure>
    <time_frame>9 months</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Protocol MI (Including Q-wave or Non-Q-wave)</measure>
    <time_frame>12 months</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Protocol MI (Including Q-wave or Non-Q-wave)</measure>
    <time_frame>24 months</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Protocol MI (TV-MI)</measure>
    <time_frame>30 days</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Protocol MI (TV-MI)</measure>
    <time_frame>6 months</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Protocol MI (TV-MI)</measure>
    <time_frame>9 months</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Protocol MI (TV-MI)</measure>
    <time_frame>12 months</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Protocol MI (TV-MI)</measure>
    <time_frame>24 months</time_frame>
    <description>This is one of the secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Complications</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Complications</measure>
    <time_frame>9 months</time_frame>
    <description>Secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Complications</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Complications</measure>
    <time_frame>24 months</time_frame>
    <description>Secondary safety endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite / Probable Stent Thrombosis</measure>
    <time_frame>Acute (&lt;1 day)</time_frame>
    <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite / Probable Stent Thrombosis</measure>
    <time_frame>Subacute (1 - 30 days)</time_frame>
    <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite / Probable Stent Thrombosis</measure>
    <time_frame>Early (0 - 30 days)</time_frame>
    <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite / Probable Stent Thrombosis</measure>
    <time_frame>Late (31 - 365 days)</time_frame>
    <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite / Probable Stent Thrombosis</measure>
    <time_frame>Very late (366 - 772 days)</time_frame>
    <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite / Probable Stent Thrombosis</measure>
    <time_frame>Overall (0 - 772 days)</time_frame>
    <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Device Success</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>Per-protocol device success is defined as the achievement of a final in-stent residual diameter stenosis (DS) of &lt; 50% by Quantitative Coronary Angiography (QCA), using only the assigned device, and occurring without a device malfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Procedure Success</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>Per-protocol procedure success is defined as the achievement of a final in-stent DS of &lt; 50% (by online QCA or visual estimation), using the assigned device and with any adjunctive devices, and occurring without cardiac death, MI (including Q-wave or non-Q-wave), or repeat revascularization of the target lesion during the hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>On day 0, during the procedure.</time_frame>
    <description>This is the procedure related endpoint. Procedure time is defined as time between insertion of the first guiding catheter until removal of the last guiding catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Contrast Used</measure>
    <time_frame>On day 0, during the procedure.</time_frame>
    <description>Defined as total amount used from insertion of the first guiding catheter until removal of the last guiding catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy Time</measure>
    <time_frame>On day 0, during the procedure.</time_frame>
    <description>This is the procedure related endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>XIENCE V EECSS Excellent Overall Performance and Deliverability Using the XIENCE V EECSS Performance Evaluation Questionnaire</measure>
    <time_frame>During the procedure</time_frame>
    <description>A related secondary performance goal for XIENCE V EECSS is the physician-determined evaluation of acute performance, deliverability, and resource utilization. XIENCE V EECSS acute performance and deliverability were determined using the XIENCE V EECSS Performance Evaluation Questionnaire. Possible responses included strongly agree,moderately agree, agree, moderately disagree, and strongly disagree. Study physicians who enrolled patients into the study were reported for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up Late Loss</measure>
    <time_frame>≥13 months.</time_frame>
    <description>This is one of the Secondary Angiographic Endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up In-stent Minimum Lumen Diameter (MLD)</measure>
    <time_frame>≥13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up In-stent Percent Diameter Stenosis (DS)</measure>
    <time_frame>≥13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up In-stent Angiographic Binary Restenosis (ABR)</measure>
    <time_frame>≥13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up In-segment Minimum Lumen Diameter (MLD)</measure>
    <time_frame>≥13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up In-segment Percent Diameter Stenosis (DS)</measure>
    <time_frame>≥13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up In-segment Angiographic Binary Restenosis (ABR)</measure>
    <time_frame>≥13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis</measure>
    <time_frame>pre procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>post procedure on 0 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Gain</measure>
    <time_frame>post procedure on 0 day</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>ID-TVF Rate in Patients With Diabetic Disease</measure>
    <time_frame>24 months</time_frame>
    <description>ID-TVF rate in All Diabetes patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TVF Rate in Patients Without Diabetic Disease</measure>
    <time_frame>24 months</time_frame>
    <description>ID-TVF rate in Non Diabetes</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TVF Rate in Single Lesion Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>ID-TVF rate in Patients with single lesion treated during the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TVF Rate in Dual Lesion Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>ID-TVF rate in Patients with dual lesion treated during the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TVF Rate in Single Vessel Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>ID-TVF rate in Patients with single vessels treated during the index procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TVF Rate in Dual Vessel Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>ID-TVF rate in Patients with dual vessel treated during the index procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Composite of ST, All Death, and All MI Rate in Patients With Diabetic Disease.</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of ST, all death, and all MI rate in All Diabetes patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Composite of ST, All Death, and All MI Rate in Patients Without Diabetic Disease</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of ST, all death, and all MI rate in Non Diabetes</description>
  </other_outcome>
  <other_outcome>
    <measure>The Composite of ST, All Death, and All MI Rate in Single Lesion Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of ST, all death, and all MI rate in Patients with single lesion treated during the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>The Composite of ST, All Death, and All MI Rate in Dual Lesion Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of ST, all death, and all MI rate in Patients with dual lesion treated during the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>The Composite of ST, All Death, and All MI Rate in Single Vessel Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of ST, all death, and all MI rate in Patients with single vessels treated during the index procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Composite of ST, All Death, and All MI Rate in Dual Vessel Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of ST, all death, and all MI rate in Patients with dual vessel treated during the index procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TLR Rate in Patients With Diabetic Disease.</measure>
    <time_frame>24 months</time_frame>
    <description>Ischemia-driven target lesion revascularization rate in All Diabetes patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TLR Rate in Patients Without Diabetic Disease</measure>
    <time_frame>24 months</time_frame>
    <description>Ischemia-driven target lesion revascularization rate in Non Diabetes</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TLR Rate in Single Lesion Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>Ischemia-driven target lesion revascularization rate in Patients with single lesion treated during the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TLR Rate in Dual Lesion Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>Ischemia-driven target lesion revascularization rate in Patients with dual lesion treated during the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TLR Rate in Single Vessel Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>Ischemia-driven target lesion revascularization rate in Patients with single vessels treated during the index procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>ID-TLR Rate in Dual Vessel Treated Subgroup</measure>
    <time_frame>24 months</time_frame>
    <description>Ischemia-driven target lesion revascularization rate in Patients with dual vessel treated during the index procedure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">546</enrollment>
  <condition>Coronary Occlusion</condition>
  <condition>Thrombosis (Stent Thrombosis)</condition>
  <condition>Vascular Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>XIENCE V EECSS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will receive this stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYPHER SELECT PLUS SECSS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will receive this stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V EECSS</intervention_name>
    <description>Patients who will receive this stent.</description>
    <arm_group_label>XIENCE V EECSS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CYPHER SELECT PLUS SECSS</intervention_name>
    <description>Patients who will receive this stent.</description>
    <arm_group_label>CYPHER SELECT PLUS SECSS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General Inclusion Criteria

               1. Patient must be at least 18 years of age

               2. The patient or patient's legally-authorized representative agrees to participate
                  in this study by signing the Ethics Committee (EC)-approved ICF prior to
                  procedure.

               3. Patient must agree to undergo all protocol-required follow-ups until the
                  completion of his/her 2-year follow-up.

               4. Patient must not currently be and must agree not to become a participant in any
                  other clinical trial until completion of his/her 2-year follow-up.

        Angiographic Inclusion Criteria

          1. Target lesion(s) must be located in a native de novo coronary artery with a visually
             estimated diameter between ≥ 2.25 and ≤ 4.0 mm.

          2. Target lesion(s) must measure ≤ 28 mm in length by visual estimation.

          3. A maximum of two de novo lesions can be treated, ie,

               1. One lesion in one vessel, OR

               2. One lesion in each of two vessels, OR

               3. Two lesions in one vessel

        Exclusion Criteria:

          -  General Exclusion Criteria

               1. Pregnant or nursing patients and those who plan pregnancy in the period up to 1
                  year post index procedure

               2. Patients with known renal insufficiency or failure (eg, serum creatinine level of
                  &gt; 2.5 mg/dL, or patient is on dialysis)

               3. Patient had an MI within 72 hours and creatine kinase-myocardial band isoenzyme
                  (CK-MB) has not returned to the normal range at the index procedure

               4. Non-study PCI for lesions in a target vessel (including side branches) has been
                  performed within 1 year prior to the index procedure

               5. Patient has a planned PCI (staged procedure) within 6 months from the date of the
                  index procedure

               6. Left ventricular ejection fraction (LVEF) of &lt; 30%.

               7. Any planned surgery necessitating discontinuation of antiplatelet therapy within
                  1 year

               8. Patient's current medical condition has a life expectancy of &lt; 2 years

               9. Patient meets contraindications of the IFU

        Angiographic Exclusion Criteria

          1. Lesion located within an arterial or saphenous vein graft or distal to a diseased
             arterial or saphenous vein graft

          2. Lesion located in left main coronary artery

          3. Ostial lesion (within 3 mm of the aorta junction, or origin of the left anterior
             descending or left circumflex arteries)

          4. Involves a bifurcation in which the side branch is ≥ 2 mm in diameter AND the ostium
             of the side branch is &gt; 50% stenosed by visual estimation

          5. Total occluded lesions (TIMI=0)

          6. Restenotic lesions

          7. Thrombus-containing vessel

          8. Extreme angulation (≥ 90º) proximal to or within the lesion

          9. Excessive tortuosity proximal to or within the lesion

         10. Heavy calcification
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao Runlin, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Wai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fu Wai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Authorized Representative in China Guidant International Trading (Shanghai) Co., Ltd.</name>
      <address>
        <city>Shanghai</city>
        <zip>200122</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <results_first_submitted>May 17, 2016</results_first_submitted>
  <results_first_submitted_qc>July 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2016</results_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting stents</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 488 patients in the Per-protocol (PP) population for final analysis. First Patient Enrolled on August 18, 2010, Last Patient Enrolled on August 31, 2011 and the Final Database Lock was on September 26, 2013. The total patient enrollment rate was 0.5 patients/site/week based on 489 patients enrolled over 54 weeks at 20 sites.</recruitment_details>
      <pre_assignment_details>All of the 546 patients, 57 (28:XIENCE;29:CYPHER)were excluded from the Per-protocol (PP) population, leaving a baseline population of 489 patients. Whereas because of patient disposition results in a total of 488 patients in the PP population for final analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE V EECSS</title>
          <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
        </group>
        <group group_id="P2">
          <title>CYPHER SELECT PLUS SECSS</title>
          <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="367"/>
                <participants group_id="P2" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All of the 546 patients, 57 were excluded from the Per-protocol (PP) population, leaving a baseline population of 489 patients and a total of 488 patients (Based on angiographic follow-up) in the PP population for final analysis. In which 367 were randomized to receive XIENCE V EECSS and 121 to CYPHER SELECT Plus SECSS group.</population>
      <group_list>
        <group group_id="B1">
          <title>XIENCE V EECSS</title>
          <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
        </group>
        <group group_id="B2">
          <title>CYPHER SELECT PLUS SECSS</title>
          <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="367"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="488"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.60" spread="10.65"/>
                    <measurement group_id="B2" value="58.74" spread="9.12"/>
                    <measurement group_id="B3" value="58.64" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age ≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>In-stent Late Loss (LL)</title>
        <description>This is the primary angiographic endpoint.
In-stent LL: The difference between the minimum lumen diameter (MLD) immediately after stent deployment and the MLD at follow-up (within stent)</description>
        <time_frame>&gt;=13 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent Late Loss (LL)</title>
          <description>This is the primary angiographic endpoint.
In-stent LL: The difference between the minimum lumen diameter (MLD) immediately after stent deployment and the MLD at follow-up (within stent)</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.28"/>
                    <measurement group_id="O2" value="0.21" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
        <description>This is the primary efficacy endpoint. Ischemia-driven target vessel failure is defined as the composite of cardiac death, all myocardial infarction (MI) and ischemia-driven target vessel revascularization (ID-TVR).</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
          <description>This is the primary efficacy endpoint. Ischemia-driven target vessel failure is defined as the composite of cardiac death, all myocardial infarction (MI) and ischemia-driven target vessel revascularization (ID-TVR).</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="2.51" upper_limit="6.98"/>
                    <measurement group_id="O2" value="6.6" lower_limit="2.90" upper_limit="12.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Composite of ST (Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave)</title>
        <description>The primary composite safety endpoint was the incidence of the composite of ST (definite and probable), all death (cardiac, vascular and non-cardiovascular), and all MI (including Q-wave and non–Q-wave).</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of ST (Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave)</title>
          <description>The primary composite safety endpoint was the incidence of the composite of ST (definite and probable), all death (cardiac, vascular and non-cardiovascular), and all MI (including Q-wave and non–Q-wave).</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.60" upper_limit="3.52"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.20" upper_limit="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
        <description>Incidence of composite of cardiac death, all MI (including Q-wave and non– Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
          <description>Incidence of composite of cardiac death, all MI (including Q-wave and non– Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
        <description>Incidence of composite of cardiac death, all MI (including Q-wave and non– Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG]).</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
          <description>Incidence of composite of cardiac death, all MI (including Q-wave and non– Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG]).</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
        <description>Incidence of composite of cardiac death, all MI (including Q-wave and non– Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
          <description>Incidence of composite of cardiac death, all MI (including Q-wave and non– Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
        <description>Incidence of composite of cardiac death, all MI (including Q-wave and non– Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Vessel Failure (ID-TVF)</title>
          <description>Incidence of composite of cardiac death, all MI (including Q-wave and non– Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG])</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave).</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave).</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave).</title>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave).</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave)</title>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave)</title>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non–Q-wave)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Lesion Revascularization (ID-TLR) (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])</title>
        <description>The is the major Secondary Efficacy Endpoint.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Lesion Revascularization (ID-TLR) (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])</title>
          <description>The is the major Secondary Efficacy Endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.77" upper_limit="3.89"/>
                    <measurement group_id="O2" value="3.3" lower_limit="0.91" upper_limit="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
        <description>Incidence of composite of cardiac death, MI attributed to the TV and ID-TLR</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
          <description>Incidence of composite of cardiac death, MI attributed to the TV and ID-TLR</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
        <description>Incidence of composite of cardiac death, MI attributed to the TV and ID-TLR</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
          <description>Incidence of composite of cardiac death, MI attributed to the TV and ID-TLR</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
        <description>This is one of the Secondary Composite Endpoints.</description>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
          <description>This is one of the Secondary Composite Endpoints.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
        <description>This is one of the Secondary Composite Endpoints.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
          <description>This is one of the Secondary Composite Endpoints.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
        <description>This is one of the Secondary Composite Endpoints.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia-driven Target Lesion Failure (ID-TLF)</title>
          <description>This is one of the Secondary Composite Endpoints.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non–Q-wave) Attributed to the Target Vessel (TV)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
        <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
          <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
        <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
          <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
        <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
          <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
        <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
          <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
        <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG)</title>
          <description>This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (Cardiac Death, All MI and TLR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
        <time_frame>30 Days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
        <time_frame>6 Months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
        <time_frame>9 Months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
        <description>One of the Secondary Safety Endpoint was all revascularization rates (target lesion, target vessel, non-target lesion, and non-target vessel) (PCI and CABG).</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization (TLR, TVR, and Non-TVR)</title>
          <description>One of the Secondary Safety Endpoint was all revascularization rates (target lesion, target vessel, non-target lesion, and non-target vessel) (PCI and CABG).</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death</title>
        <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death</title>
          <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death</title>
        <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death</title>
          <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death</title>
        <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death</title>
          <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death</title>
        <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death</title>
          <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death</title>
        <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Death</title>
          <description>This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>All Protocol MI (Including Q-wave or Non–Q-wave)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Protocol MI (TV-MI)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Protocol MI (TV-MI)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Protocol MI (TV-MI)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Protocol MI (TV-MI)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Protocol MI (TV-MI)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Protocol MI (TV-MI)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Protocol MI (TV-MI)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Protocol MI (TV-MI)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Protocol MI (TV-MI)</title>
        <description>This is one of the secondary safety endpoint.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Protocol MI (TV-MI)</title>
          <description>This is one of the secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Complications</title>
        <description>Secondary safety endpoint.</description>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding Complications</title>
          <description>Secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Complications</title>
        <description>Secondary safety endpoint.</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding Complications</title>
          <description>Secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Complications</title>
        <description>Secondary safety endpoint.</description>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding Complications</title>
          <description>Secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Complications</title>
        <description>Secondary safety endpoint.</description>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding Complications</title>
          <description>Secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Complications</title>
        <description>Secondary safety endpoint.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding Complications</title>
          <description>Secondary safety endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="360"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite / Probable Stent Thrombosis</title>
        <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
        <time_frame>Acute (&lt;1 day)</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Definite / Probable Stent Thrombosis</title>
          <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite / Probable Stent Thrombosis</title>
        <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
        <time_frame>Subacute (1 – 30 days)</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Definite / Probable Stent Thrombosis</title>
          <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite / Probable Stent Thrombosis</title>
        <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
        <time_frame>Early (0 – 30 days)</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Definite / Probable Stent Thrombosis</title>
          <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite / Probable Stent Thrombosis</title>
        <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
        <time_frame>Late (31 – 365 days)</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Definite / Probable Stent Thrombosis</title>
          <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite / Probable Stent Thrombosis</title>
        <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
        <time_frame>Very late (366 – 772 days)</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Definite / Probable Stent Thrombosis</title>
          <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite / Probable Stent Thrombosis</title>
        <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
        <time_frame>Overall (0 - 772 days)</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Definite / Probable Stent Thrombosis</title>
          <description>Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
        <time_frame>30 days</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2"/>
                    <measurement group_id="O2" value="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
        <time_frame>6 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2"/>
                    <measurement group_id="O2" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
        <time_frame>9 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1"/>
                    <measurement group_id="O2" value="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5"/>
                    <measurement group_id="O2" value="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Compliance With Dual Antiplatelet Therapy (DAPT)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                    <measurement group_id="O2" value="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Device Success</title>
        <description>Per-protocol device success is defined as the achievement of a final in-stent residual diameter stenosis (DS) of &lt; 50% by Quantitative Coronary Angiography (QCA), using only the assigned device, and occurring without a device malfunction.</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Device Success</title>
          <description>Per-protocol device success is defined as the achievement of a final in-stent residual diameter stenosis (DS) of &lt; 50% by Quantitative Coronary Angiography (QCA), using only the assigned device, and occurring without a device malfunction.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2"/>
                    <measurement group_id="O2" value="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Procedure Success</title>
        <description>Per-protocol procedure success is defined as the achievement of a final in-stent DS of &lt; 50% (by online QCA or visual estimation), using the assigned device and with any adjunctive devices, and occurring without cardiac death, MI (including Q-wave or non–Q-wave), or repeat revascularization of the target lesion during the hospital stay.</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Procedure Success</title>
          <description>Per-protocol procedure success is defined as the achievement of a final in-stent DS of &lt; 50% (by online QCA or visual estimation), using the assigned device and with any adjunctive devices, and occurring without cardiac death, MI (including Q-wave or non–Q-wave), or repeat revascularization of the target lesion during the hospital stay.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1"/>
                    <measurement group_id="O2" value="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Time</title>
        <description>This is the procedure related endpoint. Procedure time is defined as time between insertion of the first guiding catheter until removal of the last guiding catheter.</description>
        <time_frame>On day 0, during the procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time</title>
          <description>This is the procedure related endpoint. Procedure time is defined as time between insertion of the first guiding catheter until removal of the last guiding catheter.</description>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="19.3"/>
                    <measurement group_id="O2" value="28.6" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Contrast Used</title>
        <description>Defined as total amount used from insertion of the first guiding catheter until removal of the last guiding catheter.</description>
        <time_frame>On day 0, during the procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Contrast Used</title>
          <description>Defined as total amount used from insertion of the first guiding catheter until removal of the last guiding catheter.</description>
          <units>Milliliter</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.1" spread="53.2"/>
                    <measurement group_id="O2" value="145.4" spread="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluoroscopy Time</title>
        <description>This is the procedure related endpoint.</description>
        <time_frame>On day 0, during the procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluoroscopy Time</title>
          <description>This is the procedure related endpoint.</description>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="4.7"/>
                    <measurement group_id="O2" value="7.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>XIENCE V EECSS Excellent Overall Performance and Deliverability Using the XIENCE V EECSS Performance Evaluation Questionnaire</title>
        <description>A related secondary performance goal for XIENCE V EECSS is the physician-determined evaluation of acute performance, deliverability, and resource utilization. XIENCE V EECSS acute performance and deliverability were determined using the XIENCE V EECSS Performance Evaluation Questionnaire. Possible responses included strongly agree,moderately agree, agree, moderately disagree, and strongly disagree. Study physicians who enrolled patients into the study were reported for this outcome measure.</description>
        <time_frame>During the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>XIENCE V EECSS Excellent Overall Performance and Deliverability Using the XIENCE V EECSS Performance Evaluation Questionnaire</title>
          <description>A related secondary performance goal for XIENCE V EECSS is the physician-determined evaluation of acute performance, deliverability, and resource utilization. XIENCE V EECSS acute performance and deliverability were determined using the XIENCE V EECSS Performance Evaluation Questionnaire. Possible responses included strongly agree,moderately agree, agree, moderately disagree, and strongly disagree. Study physicians who enrolled patients into the study were reported for this outcome measure.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-up Late Loss</title>
        <description>This is one of the Secondary Angiographic Endpoint.</description>
        <time_frame>≥13 months.</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-up Late Loss</title>
          <description>This is one of the Secondary Angiographic Endpoint.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-Segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.35"/>
                    <measurement group_id="O2" value="0.27" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.34"/>
                    <measurement group_id="O2" value="0.33" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.32"/>
                    <measurement group_id="O2" value="0.20" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-up In-stent Minimum Lumen Diameter (MLD)</title>
        <time_frame>≥13 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-up In-stent Minimum Lumen Diameter (MLD)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="0.50"/>
                    <measurement group_id="O2" value="2.63" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-up In-stent Percent Diameter Stenosis (DS)</title>
        <time_frame>≥13 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-up In-stent Percent Diameter Stenosis (DS)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" spread="10.18"/>
                    <measurement group_id="O2" value="11.82" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-up In-stent Angiographic Binary Restenosis (ABR)</title>
        <time_frame>≥13 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-up In-stent Angiographic Binary Restenosis (ABR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-up In-segment Minimum Lumen Diameter (MLD)</title>
        <time_frame>≥13 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-up In-segment Minimum Lumen Diameter (MLD)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="0.52"/>
                    <measurement group_id="O2" value="2.33" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-up In-segment Percent Diameter Stenosis (DS)</title>
        <time_frame>≥13 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-up In-segment Percent Diameter Stenosis (DS)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.79" spread="12.36"/>
                    <measurement group_id="O2" value="18.79" spread="12.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow-up In-segment Angiographic Binary Restenosis (ABR)</title>
        <time_frame>≥13 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-up In-segment Angiographic Binary Restenosis (ABR)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis</title>
        <time_frame>pre procedure</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.97" spread="11.90"/>
                    <measurement group_id="O2" value="64.95" spread="12.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <time_frame>post procedure on 0 day</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>in-stent %DS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.09" spread="6.31"/>
                    <measurement group_id="O2" value="8.56" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in-segment %DS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.40" spread="8.09"/>
                    <measurement group_id="O2" value="12.46" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Gain</title>
        <time_frame>post procedure on 0 day</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Gain</title>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-Stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.44"/>
                    <measurement group_id="O2" value="1.77" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-Segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.49"/>
                    <measurement group_id="O2" value="1.52" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.53"/>
                    <measurement group_id="O2" value="2.06" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.54"/>
                    <measurement group_id="O2" value="1.60" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TVF Rate in Patients With Diabetic Disease</title>
        <description>ID-TVF rate in All Diabetes patients.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TVF Rate in Patients With Diabetic Disease</title>
          <description>ID-TVF rate in All Diabetes patients.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TVF Rate in Patients Without Diabetic Disease</title>
        <description>ID-TVF rate in Non Diabetes</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TVF Rate in Patients Without Diabetic Disease</title>
          <description>ID-TVF rate in Non Diabetes</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TVF Rate in Single Lesion Treated Subgroup</title>
        <description>ID-TVF rate in Patients with single lesion treated during the index procedure</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TVF Rate in Single Lesion Treated Subgroup</title>
          <description>ID-TVF rate in Patients with single lesion treated during the index procedure</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TVF Rate in Dual Lesion Treated Subgroup</title>
        <description>ID-TVF rate in Patients with dual lesion treated during the index procedure</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TVF Rate in Dual Lesion Treated Subgroup</title>
          <description>ID-TVF rate in Patients with dual lesion treated during the index procedure</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TVF Rate in Single Vessel Treated Subgroup</title>
        <description>ID-TVF rate in Patients with single vessels treated during the index procedure.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TVF Rate in Single Vessel Treated Subgroup</title>
          <description>ID-TVF rate in Patients with single vessels treated during the index procedure.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TVF Rate in Dual Vessel Treated Subgroup</title>
        <description>ID-TVF rate in Patients with dual vessel treated during the index procedure.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TVF Rate in Dual Vessel Treated Subgroup</title>
          <description>ID-TVF rate in Patients with dual vessel treated during the index procedure.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Composite of ST, All Death, and All MI Rate in Patients With Diabetic Disease.</title>
        <description>The composite of ST, all death, and all MI rate in All Diabetes patients.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite of ST, All Death, and All MI Rate in Patients With Diabetic Disease.</title>
          <description>The composite of ST, all death, and all MI rate in All Diabetes patients.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Composite of ST, All Death, and All MI Rate in Patients Without Diabetic Disease</title>
        <description>The composite of ST, all death, and all MI rate in Non Diabetes</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite of ST, All Death, and All MI Rate in Patients Without Diabetic Disease</title>
          <description>The composite of ST, all death, and all MI rate in Non Diabetes</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Composite of ST, All Death, and All MI Rate in Single Lesion Treated Subgroup</title>
        <description>The composite of ST, all death, and all MI rate in Patients with single lesion treated during the index procedure</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite of ST, All Death, and All MI Rate in Single Lesion Treated Subgroup</title>
          <description>The composite of ST, all death, and all MI rate in Patients with single lesion treated during the index procedure</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Composite of ST, All Death, and All MI Rate in Dual Lesion Treated Subgroup</title>
        <description>The composite of ST, all death, and all MI rate in Patients with dual lesion treated during the index procedure</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite of ST, All Death, and All MI Rate in Dual Lesion Treated Subgroup</title>
          <description>The composite of ST, all death, and all MI rate in Patients with dual lesion treated during the index procedure</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Composite of ST, All Death, and All MI Rate in Single Vessel Treated Subgroup</title>
        <description>The composite of ST, all death, and all MI rate in Patients with single vessels treated during the index procedure.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite of ST, All Death, and All MI Rate in Single Vessel Treated Subgroup</title>
          <description>The composite of ST, all death, and all MI rate in Patients with single vessels treated during the index procedure.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Composite of ST, All Death, and All MI Rate in Dual Vessel Treated Subgroup</title>
        <description>The composite of ST, all death, and all MI rate in Patients with dual vessel treated during the index procedure.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite of ST, All Death, and All MI Rate in Dual Vessel Treated Subgroup</title>
          <description>The composite of ST, all death, and all MI rate in Patients with dual vessel treated during the index procedure.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TLR Rate in Patients With Diabetic Disease.</title>
        <description>Ischemia-driven target lesion revascularization rate in All Diabetes patients.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TLR Rate in Patients With Diabetic Disease.</title>
          <description>Ischemia-driven target lesion revascularization rate in All Diabetes patients.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TLR Rate in Patients Without Diabetic Disease</title>
        <description>Ischemia-driven target lesion revascularization rate in Non Diabetes</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TLR Rate in Patients Without Diabetic Disease</title>
          <description>Ischemia-driven target lesion revascularization rate in Non Diabetes</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TLR Rate in Single Lesion Treated Subgroup</title>
        <description>Ischemia-driven target lesion revascularization rate in Patients with single lesion treated during the index procedure</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TLR Rate in Single Lesion Treated Subgroup</title>
          <description>Ischemia-driven target lesion revascularization rate in Patients with single lesion treated during the index procedure</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TLR Rate in Dual Lesion Treated Subgroup</title>
        <description>Ischemia-driven target lesion revascularization rate in Patients with dual lesion treated during the index procedure</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TLR Rate in Dual Lesion Treated Subgroup</title>
          <description>Ischemia-driven target lesion revascularization rate in Patients with dual lesion treated during the index procedure</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TLR Rate in Single Vessel Treated Subgroup</title>
        <description>Ischemia-driven target lesion revascularization rate in Patients with single vessels treated during the index procedure.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TLR Rate in Single Vessel Treated Subgroup</title>
          <description>Ischemia-driven target lesion revascularization rate in Patients with single vessels treated during the index procedure.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ID-TLR Rate in Dual Vessel Treated Subgroup</title>
        <description>Ischemia-driven target lesion revascularization rate in Patients with dual vessel treated during the index procedure.</description>
        <time_frame>24 months</time_frame>
        <population>The number of participants with angiographic follow up available was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V EECSS</title>
            <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER SELECT PLUS SECSS</title>
            <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
          </group>
        </group_list>
        <measure>
          <title>ID-TLR Rate in Dual Vessel Treated Subgroup</title>
          <description>Ischemia-driven target lesion revascularization rate in Patients with dual vessel treated during the index procedure.</description>
          <population>The number of participants with angiographic follow up available was analysed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>XIENCE V EECSS</title>
          <description>Patients who will receive this stent.
XIENCE V EECSS: Patients who will receive this stent.</description>
        </group>
        <group group_id="E2">
          <title>CYPHER SELECT PLUS SECSS</title>
          <description>Patients who will receive this stent.
CYPHER SELECT PLUS SECSS: Patients who will receive this stent.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="360"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block (AVB)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Coronary Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Coronary Heart Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Fibrillation Atrial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hear Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Unstable Angina</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Extrasystole; Fibrillation Atrial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Coronary heart disease (CHD), Coronary Revascularization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Paroxysmal Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Ulcer With Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatine kinase MB (CK-MB) increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Liver Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Fail, Chronic Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Non-Targeted Vessel Revascularization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Revascularization</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Target Lesion Revascularization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Non-Target Vascular Stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Target Vessel Revasculization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Non-Target Vessel Restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Myocardial infarction (MI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Distress Because Of Air Pollution</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Chest Distress Occasionally</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Chest Pain Happens More Frequently</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Chest Tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Premature Beat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Breathing Difficulty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatine kinase-MB (CK-MB0 Increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T increased (cTnI)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="360"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T of Post-Procedure Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>The Cardiac Enzyme Is Higher</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Abnormal troponin I (TnI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Troponin I (TnI) Increase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="360"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Troponin I (TnI) Increase Significantly</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Troponin I (TnI) Of Post Procedure Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Troponin T (TnT) of Post Procedure Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Peri-procedural PCI and MI</sub_title>
                <description>Peri-procedural percutaneous coronary intervention (PCI) and peri-procedural myocardial infarction</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vessel Interlayer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Complication of percutaneous coronary intervention (PCI) Procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dana Haudek</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>928-925-4054</phone>
      <email>dana.haudek@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

